Anna R. Mironova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna R. Mironova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Galina N. Nikiforova
Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications - Anna Vladimirovna Zolotova
Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Mikhail Valerievich Svistushkin
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Elena A. Shevchik
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Valerii M. Svistushkin
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - A. B. Maltsev
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication
Latest Publications
- 18 November 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 91 (5)
Optimizing the treatment of patients with acute non-streptococcal tonsillopharyngitis: focusing on the impact on all stages of the etiopathogenesis
Acute tonsillopharyngitis (ATP) is one of the most common reasons for patients seeking primary care in both pediatric and adult practice. This disease is characterized by inflammatory changes in the mucosa and lymphatic structures of the oropharynx. The etiological structure of ATP is heterogeneous, but viruses play a leading role. Despite the long-term scientific and practical interest of doctors in the study of etiopathogenesis and the treatment of patients with this pathology, a significant number of diagnostic and therapeutic errors remain in real clinical practice, leading to polypharmacy and, first of all, to the unjustified prescription of systemic antibacterial drugs. These circumstances contribute to the suppression of the normal microbiota of the human body, an increase in antibiotic resistance of pathogens, an increase in the cost of treatment and the risk of adverse drug reactions. In acute non-streptococcal tonsillopharyngitis, antibacterial therapy is not indicated. Treatment of such patients should be directed to all links of etiopathogenesis, with the minimum sufficient use of drugs. Patients with viral ATP need effective relief of symptoms and prevention of bacterial complications. In this aspect, standardized herbal medicine can play an important role. Herbal drugs have a multicomponent effect, including anti-inflammatory, antiseptic, immunomodulatory and reparative effects. This makes them optimal agents for the therapy of viral inflammatory diseases of the pharynx. Particular attention should be paid to Tonsilgon N—the original herbal medicinal product with complex effect, produced by Bionorica company in Germany according to the unique concept of phytoneering. The staff of the Department of Ear, Throat and Nose Diseases of the Sechenov Moscow State Medical University studied the effectiveness of the Tonsilgon N use in the treatment of patients with acute non-bacterial tonsillopharyngitis. The results of the study showed that the use of Tonsilgon H in the treatment of patients with acute non-bacterial tonsillopharyngitis is safe and effective, and contributes to a faster reduction in the severity of clinical symptoms compared to the use of topical therapy alone.
- 18 November 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 91 (5)
Optimizing the treatment of patients with acute non-streptococcal tonsillopharyngitis: focusing on the impact on all stages of the etiopathogenesis
Acute tonsillopharyngitis (ATP) is one of the most common reasons for patients seeking primary care in both pediatric and adult practice. This disease is characterized by inflammatory changes in the mucosa and lymphatic structures of the oropharynx. The etiological structure of ATP is heterogeneous, but viruses play a leading role. Despite the long-term scientific and practical interest of doctors in the study of etiopathogenesis and the treatment of patients with this pathology, a significant number of diagnostic and therapeutic errors remain in real clinical practice, leading to polypharmacy and, first of all, to the unjustified prescription of systemic antibacterial drugs. These circumstances contribute to the suppression of the normal microbiota of the human body, an increase in antibiotic resistance of pathogens, an increase in the cost of treatment and the risk of adverse drug reactions. In acute non-streptococcal tonsillopharyngitis, antibacterial therapy is not indicated. Treatment of such patients should be directed to all links of etiopathogenesis, with the minimum sufficient use of drugs. Patients with viral ATP need effective relief of symptoms and prevention of bacterial complications. In this aspect, standardized herbal medicine can play an important role. Herbal drugs have a multicomponent effect, including anti-inflammatory, antiseptic, immunomodulatory and reparative effects. This makes them optimal agents for the therapy of viral inflammatory diseases of the pharynx. Particular attention should be paid to Tonsilgon N—the original herbal medicinal product with complex effect, produced by Bionorica company in Germany according to the unique concept of phytoneering. The staff of the Department of Ear, Throat and Nose Diseases of the Sechenov Moscow State Medical University studied the effectiveness of the Tonsilgon N use in the treatment of patients with acute non-bacterial tonsillopharyngitis. The results of the study showed that the use of Tonsilgon H in the treatment of patients with acute non-bacterial tonsillopharyngitis is safe and effective, and contributes to a faster reduction in the severity of clinical symptoms compared to the use of topical therapy alone.
- Open Access
- 21 June 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (3) , 200-204
What is hidden under the mask of chronic suppurative otitis media? Clinical case
Chronic suppurative otitis media (CSOM) is a common pathology in the practice of an otolaryngologist. Modern conservative therapy and surgical correction methods have made it possible to achieve good functional results. However, in some cases, standard treatment is ineffective, then such a course of CSOM is usually called ”atypical”. Under its mask, a number of systemic diseases may be hidden, which are accompanied by inflammatory changes in the cavities of the middle ear. The article describes a clinical case of ”atypical” bilateral purulent otitis media in a female patient. During surgical treatment, morphological features were noted indicating a possible specific nature of inflammation in the middle ear. During further examination by a phthisiatrician, a tuberculoma of the right lung was detected, chemotherapy was started, during which, after 4 months, the symptoms of exacerbation of CSOM were stopped. Thus, an interdisciplinary approach is necessary for diagnosis and correct tactics of management of patients with ”atypical” sluggish CSOM.
- 21 June 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (3) , 200-204
Open AccessWhat is hidden under the mask of chronic suppurative otitis media? Clinical case
Chronic suppurative otitis media (CSOM) is a common pathology in the practice of an otolaryngologist. Modern conservative therapy and surgical correction methods have made it possible to achieve good functional results. However, in some cases, standard treatment is ineffective, then such a course of CSOM is usually called ”atypical”. Under its mask, a number of systemic diseases may be hidden, which are accompanied by inflammatory changes in the cavities of the middle ear. The article describes a clinical case of ”atypical” bilateral purulent otitis media in a female patient. During surgical treatment, morphological features were noted indicating a possible specific nature of inflammation in the middle ear. During further examination by a phthisiatrician, a tuberculoma of the right lung was detected, chemotherapy was started, during which, after 4 months, the symptoms of exacerbation of CSOM were stopped. Thus, an interdisciplinary approach is necessary for diagnosis and correct tactics of management of patients with ”atypical” sluggish CSOM.
- Open Access
- 13 October 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (9) , 587-593
Neutrophil extracellular traps as an important part of the pathogenesis of chronic rhinosinusitis without polyps
Background. Chronic sinusitis occurs in the Russian Federation in 16.4±10.89% of the population and has a great impact on the quality of life of patients. The inflammatory process underlying this pathology is often resistant to conservative treatment and causes surgical intervention. The study of the role of neutrophil extracellular traps as an important part of the immune response, as well as the capabilities of drugs capable of influencing the processes of netosis, is an important and relevant area of modern research. Aim. Studying the role of NETs in the pathogenesis of CRS without polyps, assessing the effect of azoximer bromide on the metabolism of NETs in patients with CRS. Materials and methods. The study included 82 patients diagnosed with chronic rhinosinusitis (average age 37±12 years), and 40 healthy volunteers (average age 34±10 years). Patients with CRS were treated with surgery and a course of azoximer bromide, the severity of the disease did not differ in patients. Nasal secretions and venous blood were analyzed in all study participants with the determination of surrogate markers of neutrophil extracellular traps – myeloperoxidase complexes with DNA and the detection of double-stranded DNA (Quant Pico Green dsDNA kit). In patients who received azoximer bromide, the material was taken twice – before the start of treatment and 10 days after the course of treatment. Results. In patients with CRS, the amount of NETs in nasal secretions and venous blood is higher compared to the control group (p0.05). The use of azoximer bromide in CRS outside of exacerbation reduces the activity of NETosis processes with intranasal use of the drug not only in the area of inflammation (reduction of NET in nasal secretions); p0.05, but also at the general level (decrease NETs in venous blood); p0.05. Conclusion. An increase in the amount of NETs in nasal flushes and venous blood in patients with CRS without exacerbation compared with the control group may indicate a likely pathological role of NETosis processes, and an increase in the amount of NETs in the blood of patients with CRS without exacerbation compared with the control group indicates the systemic effect of a local inflammatory process in the mucous membrane of the nasal cavity and paranasal sinuses.
- 13 October 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (9) , 587-593
Open AccessNeutrophil extracellular traps as an important part of the pathogenesis of chronic rhinosinusitis without polyps
Background. Chronic sinusitis occurs in the Russian Federation in 16.4±10.89% of the population and has a great impact on the quality of life of patients. The inflammatory process underlying this pathology is often resistant to conservative treatment and causes surgical intervention. The study of the role of neutrophil extracellular traps as an important part of the immune response, as well as the capabilities of drugs capable of influencing the processes of netosis, is an important and relevant area of modern research. Aim. Studying the role of NETs in the pathogenesis of CRS without polyps, assessing the effect of azoximer bromide on the metabolism of NETs in patients with CRS. Materials and methods. The study included 82 patients diagnosed with chronic rhinosinusitis (average age 37±12 years), and 40 healthy volunteers (average age 34±10 years). Patients with CRS were treated with surgery and a course of azoximer bromide, the severity of the disease did not differ in patients. Nasal secretions and venous blood were analyzed in all study participants with the determination of surrogate markers of neutrophil extracellular traps – myeloperoxidase complexes with DNA and the detection of double-stranded DNA (Quant Pico Green dsDNA kit). In patients who received azoximer bromide, the material was taken twice – before the start of treatment and 10 days after the course of treatment. Results. In patients with CRS, the amount of NETs in nasal secretions and venous blood is higher compared to the control group (p0.05). The use of azoximer bromide in CRS outside of exacerbation reduces the activity of NETosis processes with intranasal use of the drug not only in the area of inflammation (reduction of NET in nasal secretions); p0.05, but also at the general level (decrease NETs in venous blood); p0.05. Conclusion. An increase in the amount of NETs in nasal flushes and venous blood in patients with CRS without exacerbation compared with the control group may indicate a likely pathological role of NETosis processes, and an increase in the amount of NETs in the blood of patients with CRS without exacerbation compared with the control group indicates the systemic effect of a local inflammatory process in the mucous membrane of the nasal cavity and paranasal sinuses.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (5) , 43-50
Effectiveness of topical antibiotic therapy in the prevention of infectious and inflammatory complications after rhinosurgical interventions
Optimization of postoperative management of patients after rhinosurgery does not lose its relevance. A significant therapeutic and economic aspect is the rational prescription of systemic antibacterial therapy after conditionally clean operations. This issue is especially acute today, in conditions of the rapid formation of multiresistance in pathogens, the growth of allergic sensitization to medical substance and the comorbidity of patients. The need to have clear criteria for prescribing local and/or systemic antibacterial therapy after surgical interventions in the nasal cavity and paranasal sinuses in order to prevent infectious complications is beyond doubt. Objective. To assess the effectiveness and safety of the use of topical antibacterial medication in patients after rhinosurgery. Material and methods. 60 patients (38 were men and 22 women) aged 18 to 55 years were observed in the Clinic of Ear, Nose and Throat Diseases of the Sechenov First Moscow State Medical University, who underwent surgery under general anesthesia for non-purulent pathology of the nasal cavity and paranasal sinuses. In the postoperative period, all patients were randomly divided into two groups: the main group, which received Isofra (framecitin sulfate) intranasally, 1 dose 4 times a day for 5 days, and the control group, in which the antibiotic ceftriaxone was administered intramuscularly 1.0 g 2 times a day at the same time. In order to compare the indicators in the two groups on the 1st, 3rd and 5th days after surgery, the severity of subjective and objective symptoms was assessed using visual analogue scales (VAS). All observed patients were discharged from the hospital on the 5th day after surgery; on the 10th day, on an outpatient basis, material was collected from the mucous membrane of the nasal cavity for microbiological and cytological examination and the rate of mucociliary transport (MCT) was assessed using a saccharin test. For 3 months after discharge, all patients were called by a doctor monthly to identify episodes of acute respiratory viral infections, including the development of bacterial complications. Results. Statistically significant differences were recorded on the 5th day after surgery in terms of the severity of nasal obstruction (p<0.05) — in the main group, the degree of difficulty in nasal breathing was lower than in the control group. There were no significant differences in the results of microbiological and cytological studies, or MCT indicators; the results of the main and control groups were comparable. No adverse events were observed in patients during topical antibiotic therapy; during systemic antibacterial treatment, 3 patients experienced dyspeptic symptoms for 3-7 days. Conclusion. Thus, the antibacterial nasal spray Isofra, when used in the postoperative period, is not inferior in effectiveness to preventive systemic antibacterial therapy, which allows, taking into account the risk of the formation of resistant strains of microorganisms and the development of adverse events against the background of systemic antibacterial therapy, to significantly limit the indications for the latter.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (5) , 43-50
Effectiveness of topical antibiotic therapy in the prevention of infectious and inflammatory complications after rhinosurgical interventions
Optimization of postoperative management of patients after rhinosurgery does not lose its relevance. A significant therapeutic and economic aspect is the rational prescription of systemic antibacterial therapy after conditionally clean operations. This issue is especially acute today, in conditions of the rapid formation of multiresistance in pathogens, the growth of allergic sensitization to medical substance and the comorbidity of patients. The need to have clear criteria for prescribing local and/or systemic antibacterial therapy after surgical interventions in the nasal cavity and paranasal sinuses in order to prevent infectious complications is beyond doubt. Objective. To assess the effectiveness and safety of the use of topical antibacterial medication in patients after rhinosurgery. Material and methods. 60 patients (38 were men and 22 women) aged 18 to 55 years were observed in the Clinic of Ear, Nose and Throat Diseases of the Sechenov First Moscow State Medical University, who underwent surgery under general anesthesia for non-purulent pathology of the nasal cavity and paranasal sinuses. In the postoperative period, all patients were randomly divided into two groups: the main group, which received Isofra (framecitin sulfate) intranasally, 1 dose 4 times a day for 5 days, and the control group, in which the antibiotic ceftriaxone was administered intramuscularly 1.0 g 2 times a day at the same time. In order to compare the indicators in the two groups on the 1st, 3rd and 5th days after surgery, the severity of subjective and objective symptoms was assessed using visual analogue scales (VAS). All observed patients were discharged from the hospital on the 5th day after surgery; on the 10th day, on an outpatient basis, material was collected from the mucous membrane of the nasal cavity for microbiological and cytological examination and the rate of mucociliary transport (MCT) was assessed using a saccharin test. For 3 months after discharge, all patients were called by a doctor monthly to identify episodes of acute respiratory viral infections, including the development of bacterial complications. Results. Statistically significant differences were recorded on the 5th day after surgery in terms of the severity of nasal obstruction (p<0.05) — in the main group, the degree of difficulty in nasal breathing was lower than in the control group. There were no significant differences in the results of microbiological and cytological studies, or MCT indicators; the results of the main and control groups were comparable. No adverse events were observed in patients during topical antibiotic therapy; during systemic antibacterial treatment, 3 patients experienced dyspeptic symptoms for 3-7 days. Conclusion. Thus, the antibacterial nasal spray Isofra, when used in the postoperative period, is not inferior in effectiveness to preventive systemic antibacterial therapy, which allows, taking into account the risk of the formation of resistant strains of microorganisms and the development of adverse events against the background of systemic antibacterial therapy, to significantly limit the indications for the latter.
- Open Access
- 18 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 198-205
Evaluation of different strategies for using steroids in the treatment of sudden sensorineural hearing loss
Introduction. Sudden sensorineural hearing loss is manifested by sudden or rapid hearing loss without obvious disturbances in the outer and middle ear. Often the cause of this condition is not established. At the moment, various methods are used in the treatment, including corticosteroids, which are most often used as primary therapy. Recent studies demonstrate the effectiveness of topical steroid administration.Aim. Assess the effectiveness and safety of various methods of topical and standard systemic use dexamethasone in the treatment of patients with acute sensorineural hearing loss, as well as to determine the optimal timing of therapy.Materials and methods. 61 patients with this disease were treated in the study. 20 of them received dexamethasone transtubarly, 21 – transtympanic, and 20 – systemically. Audiological examination was performed on all patients before treatment, at discharge, a month and six months after discharge. All participants regularly assessed their discomfort on a 10-point scale. Results. The results of treatment demonstrated the effectiveness of both systemic and local steroid therapy in patients with sensorineural hearing loss; however, with topical use of the drug, the proportion of patients with complete hearing restoration was greater. Transtympanic introduction of steroids after radiowave myringotomy turned out to be the most comfortable for patients the level of discomfort was 1.5 points out of 10, while against the background of transtubal administration of the drug and systemic treatment it was 4.5 and 2.3 points, respectively.Conclusions. The method of transtympanic administration of corticosteroids in patients with acute sensorineural hearing loss after radiowave myringotomy is a reliable and effective method of drug delivery to the windows of the labyrinth. This approach allows you to visually control the process of introducing the medication into the tympanic cavity. Transtympanic and transtubal methods of steroid administration are comparable in effectiveness to classical systemic steroid therapy in the treatment of patients with acute sensorineural hearing loss.
- 18 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 198-205
Open AccessEvaluation of different strategies for using steroids in the treatment of sudden sensorineural hearing loss
Introduction. Sudden sensorineural hearing loss is manifested by sudden or rapid hearing loss without obvious disturbances in the outer and middle ear. Often the cause of this condition is not established. At the moment, various methods are used in the treatment, including corticosteroids, which are most often used as primary therapy. Recent studies demonstrate the effectiveness of topical steroid administration.Aim. Assess the effectiveness and safety of various methods of topical and standard systemic use dexamethasone in the treatment of patients with acute sensorineural hearing loss, as well as to determine the optimal timing of therapy.Materials and methods. 61 patients with this disease were treated in the study. 20 of them received dexamethasone transtubarly, 21 – transtympanic, and 20 – systemically. Audiological examination was performed on all patients before treatment, at discharge, a month and six months after discharge. All participants regularly assessed their discomfort on a 10-point scale. Results. The results of treatment demonstrated the effectiveness of both systemic and local steroid therapy in patients with sensorineural hearing loss; however, with topical use of the drug, the proportion of patients with complete hearing restoration was greater. Transtympanic introduction of steroids after radiowave myringotomy turned out to be the most comfortable for patients the level of discomfort was 1.5 points out of 10, while against the background of transtubal administration of the drug and systemic treatment it was 4.5 and 2.3 points, respectively.Conclusions. The method of transtympanic administration of corticosteroids in patients with acute sensorineural hearing loss after radiowave myringotomy is a reliable and effective method of drug delivery to the windows of the labyrinth. This approach allows you to visually control the process of introducing the medication into the tympanic cavity. Transtympanic and transtubal methods of steroid administration are comparable in effectiveness to classical systemic steroid therapy in the treatment of patients with acute sensorineural hearing loss.
- 15 May 2023
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 88 (2) , 59-66
Possibilities of using recombinant human deoxyribonuclease I in otorhinolaryngology
ВВЕДЕНИЕ Препарат дорназа альфа («Пульмозим», «Тигераза») — это очищенный раствор рекомбинантной человеческой ДНазы, разработан клинически для лечения легочных заболеваний у пациентов с муковисцидозом (МВ). Действие препарата направлено на разрушение вязкого секрета, богатого нитями ДНК нейтрофилов, путем их фрагментации, густота секрета снижается — и аэрация нижних дыхательных путей улучшается. Схожесть патологических процессов с образованием вязкого экссудата на поверхности слизистой оболочки при заболеваниях верхних дыхательных путей и уха инициировала исследования по применению дорназы альфа в оториноларингологии. МАТЕРИАЛ И МЕТОДЫ Проведен анализ материалов отечественных и зарубежных авторов по эффективности применения препарата дорназа альфа в оториноларингологии. РЕЗУЛЬТАТЫ В обзор включены 132 пациента (10 исследований), у которых препарат дорназа альфа применялся для лечения заболеваний полости носа и околоносовых пазух, ассоциированных с МВ. Анализ литературы выявил только три исследования, одно из которых состояло из двух частей, по изучению влияния дорназы альфа на экссудат среднего уха: два исследования продемонстрированы на животной модели, одно исследование — in vitro, на образцах выпота из среднего уха пациентов с рецидивирующим острым средним отитом, полученных при шунтировании, и одно исследование — клиническое, 40 пациентов (40 ушей), для гидролиза экссудата в тимпаностомических трубках. ЗАКЛЮЧЕНИЕ Анализ исследований по применению дорназы альфа демонстрирует улучшение клинической симптоматики у всех пациентов с МВ и хроническим риносинуситом. В экспериментальных исследованиях на животной модели, а также в работе in vitro (на экксудате из среднего уха) дорназа альфа продемонстрировала высокую эффективность и безопасность. Дорназа альфа — препарат с высоким потенциалом, необходимы дальнейшие исследования для более широкого применения этого препарата в лор-практике, особенно в отиатрии.
- 15 May 2023
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 88 (2) , 59-66
Possibilities of using recombinant human deoxyribonuclease I in otorhinolaryngology
ВВЕДЕНИЕ Препарат дорназа альфа («Пульмозим», «Тигераза») — это очищенный раствор рекомбинантной человеческой ДНазы, разработан клинически для лечения легочных заболеваний у пациентов с муковисцидозом (МВ). Действие препарата направлено на разрушение вязкого секрета, богатого нитями ДНК нейтрофилов, путем их фрагментации, густота секрета снижается — и аэрация нижних дыхательных путей улучшается. Схожесть патологических процессов с образованием вязкого экссудата на поверхности слизистой оболочки при заболеваниях верхних дыхательных путей и уха инициировала исследования по применению дорназы альфа в оториноларингологии. МАТЕРИАЛ И МЕТОДЫ Проведен анализ материалов отечественных и зарубежных авторов по эффективности применения препарата дорназа альфа в оториноларингологии. РЕЗУЛЬТАТЫ В обзор включены 132 пациента (10 исследований), у которых препарат дорназа альфа применялся для лечения заболеваний полости носа и околоносовых пазух, ассоциированных с МВ. Анализ литературы выявил только три исследования, одно из которых состояло из двух частей, по изучению влияния дорназы альфа на экссудат среднего уха: два исследования продемонстрированы на животной модели, одно исследование — in vitro, на образцах выпота из среднего уха пациентов с рецидивирующим острым средним отитом, полученных при шунтировании, и одно исследование — клиническое, 40 пациентов (40 ушей), для гидролиза экссудата в тимпаностомических трубках. ЗАКЛЮЧЕНИЕ Анализ исследований по применению дорназы альфа демонстрирует улучшение клинической симптоматики у всех пациентов с МВ и хроническим риносинуситом. В экспериментальных исследованиях на животной модели, а также в работе in vitro (на экксудате из среднего уха) дорназа альфа продемонстрировала высокую эффективность и безопасность. Дорназа альфа — препарат с высоким потенциалом, необходимы дальнейшие исследования для более широкого применения этого препарата в лор-практике, особенно в отиатрии.
- Open Access
- 10 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 152-159
Intranasal drugs possibilities in the treatment of patients with rhinitis medicamentosa
Introduction. The article presents the physiology of nasal breathing, as well as the problem of nasal obstruction and the mechanisms of its development. Topical issues of rhinitis medicamentosa are discussed, based on the pathogenic links of this condition. It has been established that there is no single treatment regimen for rhinitis medicamentosa at the moment.Objectives. To evaluate the effectiveness and safety of the use of intranasal drugs in patients with medical rhinitis.Materials and methods. A comparative study of the clinical use of the complex preparation Frinozol®, the active substances of which are the decongestant phenylephrine and the antihistamine drug cetirizine, intranasal glucocorticosteroid Nosefrin®, as well as their combinations, was carried out in patients with rhinitis medicamentosa.Results. The results showed that the use of Frinozol®, Nozefrin®, as well as a combination of these drugs leads to a decrease in the frequency of use of nasal decongestants, and in a larger percentage of cases or to the complete cessation of their use by patients with drug-induced rhinitis. The combination of Frinozol – Nozefrin is somewhat more effective. However, a number of patients resume the use of nasal decongestants after some time, which leads to the need for additional courses of conservative therapy. In the course of the observational study, we noted excellent and good tolerability of the drugs, and patient satisfaction with the treatment in all groups.Conclusions. The problem of drug-induced rhinitis remains unresolved, which is why the search for optimal and effective schemes for the conservative treatment of this disease continues. The use of intranasal glucocorticosteroids and topical antihistamines can significantly reduce the frequency of use of nasal decongestants, or completely abandon their use.
- 10 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 152-159
Open AccessIntranasal drugs possibilities in the treatment of patients with rhinitis medicamentosa
Introduction. The article presents the physiology of nasal breathing, as well as the problem of nasal obstruction and the mechanisms of its development. Topical issues of rhinitis medicamentosa are discussed, based on the pathogenic links of this condition. It has been established that there is no single treatment regimen for rhinitis medicamentosa at the moment.Objectives. To evaluate the effectiveness and safety of the use of intranasal drugs in patients with medical rhinitis.Materials and methods. A comparative study of the clinical use of the complex preparation Frinozol®, the active substances of which are the decongestant phenylephrine and the antihistamine drug cetirizine, intranasal glucocorticosteroid Nosefrin®, as well as their combinations, was carried out in patients with rhinitis medicamentosa.Results. The results showed that the use of Frinozol®, Nozefrin®, as well as a combination of these drugs leads to a decrease in the frequency of use of nasal decongestants, and in a larger percentage of cases or to the complete cessation of their use by patients with drug-induced rhinitis. The combination of Frinozol – Nozefrin is somewhat more effective. However, a number of patients resume the use of nasal decongestants after some time, which leads to the need for additional courses of conservative therapy. In the course of the observational study, we noted excellent and good tolerability of the drugs, and patient satisfaction with the treatment in all groups.Conclusions. The problem of drug-induced rhinitis remains unresolved, which is why the search for optimal and effective schemes for the conservative treatment of this disease continues. The use of intranasal glucocorticosteroids and topical antihistamines can significantly reduce the frequency of use of nasal decongestants, or completely abandon their use.